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Abstract 
Review on lymphomatoid papulosis (LyP) with 
6p25.3 rearrangement, with data on clinics, and the 
genes implicated. 
Clinics and pathology 
Disease 
Lymphomatoid papulosis (LyP) 
Phenotype/cell stem origin 
Mature (peripheral) T cell. 
Etiology 
No etiologic factors are known. 
Epidemiology 
All reported cases occurred in elderly adults (67-88 
years, mean 75 years) with strong male 
predominance (9M:2F) (Karai et al., 2013). 
Clinics 
The lesions are usually restricted to a single body 
area.  
Affected sites included the head and neck, upper 
torso, and extremities.  
Lesions ranged in size from 0.3 cm to 1.0 cm in 
diameter and had variable scale but no ulceration.  
No patient had disseminated cutaneous disease or 
clinical evidence of extracutaneous disease. 
Pathology 
The histological features are remarkably consistent 
and different from the other types of cutaneous 
LyPs.  
Salient features include: prominent dermal nodule 
with the overlying epidermis showing pagetoid 
reticulosis-like histological changes.  
Marked periadnexal involvement is sometimes 
present. Tumor cells are mostly small to medium-
sized with markedly irregular nuclei.  
Lesions show high mitotic rate and the presence of 
frequent apoptotic bodies.  
Necrosis is absent.  
No significant amount of eosinophils and 
neutrophils are present. 
Treatment 
No established treatment.  
Most of the lesions involute spontaneously and 
without therapy.  
Consideration to radiation, injection with kenalog 
or excision can be made depending on individual 
presentation. 
Evolution 
Similar to other types of LyP, recurring-remitting 
course. 
Prognosis 
According to the series of 11 patients the prognosis 
is good (Karai et al., 2013). 
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Lymphomatoid papulosis with 6p25.3 rearrangement. Low power H&E image shows a prominent lymphoid nodule in the dermis 
(A) with characteristic pagetoid reticulosis-like epidermal involvement (B) at medium power. Inset in (A) shows high power image 
of atypical cells with small to medium nuclei and with the presence of frequent apoptotic bodies and mitotic figures. 
Immunohistochemical stains reveal a CD3 and CD30 positive phenotype with high proliferative ratio depicted by Ki-67 (C, D, and 
E, respectively). 
 
 
Cytogenetics 
Cytogenetics morphological 
Karyotypic findings have not been reported. 
Probes 
See Karai et al., 2013. 
Additional anomalies 
Unknown. 
Variants 
Unknown. 
Genes involved and 
proteins 
Note 
The breakapart probe used to identify 6p25.3 
rearrangements in LyP spans both the DUSP22 and 
the IRF4 genes.  
The specific breakpoints have not been reported in 
LyP. In ALK-negative anaplastic large cell 
lymphomas (ALCLs), 6p25.3 breakpoints in or near 
either gene have been reported (Feldman et al., 
2011). The partner locus was confirmed to be  
7q32.3 in a single case of LyP tested, analogous to 
the t(6;7)(p25.3;q32.3) reported in ALCLs, but was 
not investigated in the remaining reported cases. 
DUSP22 
Location 
6p25.3 
Protein 
DUSP22 encodes a dual-specificity phosphatase 
that inhibits T-cell antigen-receptor signaling in T 
cells by inactivating the MAP kinase, ERK2.  
The expression and function of DUSP22 in cases of 
LyP with 6p25.3 rearrangements have not been 
reported. 
IRF4 
Location 
6p25.3 
Protein 
IRF4 encodes a transcription factor, IRF4/MUM1, 
critical in lymphocyte activation and differentiation. 
Although IRF4/MUM1 is expressed in most cases 
of LyP, the expression and function of 
IRF4/MUM1 in cases of LyP with 6p25.3 
rearrangements have not been reported. 
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Breakapart FISH for the DUSP22-IRF4 locus on 6p25.3 demonstrates abnormal separation of the red and green signals in the 
cell in the lower left (arrows). A cell with a normal signal pattern (two fusion signals, f) is seen in the upper right 
 
 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
Not known. 
Fusion protein 
Note 
Not known. 
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